Special Issues
December 2018
Volume: 7
Issue: 6
FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress
Volume: 1
Issue: 1
October 2018
Volume: 7
Issue: 5
The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas
August 2018
Volume: 7
Issue: 4
June 2018
April 2018
Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - March 2018
March 2018
February 2018
Volume: 7
Issue: 1
June 2018
Volume: 7
Issue: 3
April 2018
Volume: 7
Issue: 2
Focus on Pathways: Emerging Mutations in Lung Cancer and Other Solid Tumors
Focus on Pathways: NTRK Gene Fusions
Focus on Pathways: Therapeutic Inhibition of XPO1- Mediated Nucleocytoplasmic Transport With SINE Technology
Focus on Pathways: Next-Generation Sequencing to Support Immuno-Oncology Therapy: The Emerging Role of Tumor Mutational Burden
Focus on Pathways: Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5